CHMP recommends higher dose of Novo Nordisk's Ozempic

The EMA's expert committee, the CHMP, has reported a positive opinion of Novo Nordisk's application to extend the marketing its diabetes drug Ozempic to a new dose of 2.0 mg.
Photo: LISELOTTE SABROE//
Photo: LISELOTTE SABROE//
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

A new version of Novo Nordisk's once-weekly diabetes drug Ozempic looks to be on the road to European patients, the pharmaceutical company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading